Tags

Type your tag names separated by a space and hit enter

Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.
World J Gastroenterol. 2016 Feb 21; 22(7):2219-41.WJ

Abstract

In the last decade the impressive expansion of our knowledge of the vast microbial community that resides in the human intestine, the gut microbiota, has provided support to the concept that a disturbed intestinal ecology might promote development and maintenance of symptoms in irritable bowel syndrome (IBS). As a correlate, manipulation of gut microbiota represents a new strategy for the treatment of this multifactorial disease. A number of attempts have been made to modulate the gut bacterial composition, following the idea that expansion of bacterial species considered as beneficial (Lactobacilli and Bifidobacteria) associated with the reduction of those considered harmful (Clostridium, Escherichia coli, Salmonella, Shigella and Pseudomonas) should attenuate IBS symptoms. In this conceptual framework, probiotics appear an attractive option in terms of both efficacy and safety, while prebiotics, synbiotics and antibiotics still need confirmation. Fecal transplant is an old treatment translated from the cure of intestinal infective pathologies that has recently gained a new life as therapeutic option for those patients with a disturbed gut ecosystem, but data on IBS are scanty and randomized, placebo-controlled studies are required.

Authors+Show Affiliations

Eleonora Distrutti, Lorenzo Monaldi, S.C. di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06100 Perugia, Italy.Eleonora Distrutti, Lorenzo Monaldi, S.C. di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06100 Perugia, Italy.Eleonora Distrutti, Lorenzo Monaldi, S.C. di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06100 Perugia, Italy.Eleonora Distrutti, Lorenzo Monaldi, S.C. di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06100 Perugia, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26900286

Citation

Distrutti, Eleonora, et al. "Gut Microbiota Role in Irritable Bowel Syndrome: New Therapeutic Strategies." World Journal of Gastroenterology, vol. 22, no. 7, 2016, pp. 2219-41.
Distrutti E, Monaldi L, Ricci P, et al. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol. 2016;22(7):2219-41.
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016). Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World Journal of Gastroenterology, 22(7), 2219-41. https://doi.org/10.3748/wjg.v22.i7.2219
Distrutti E, et al. Gut Microbiota Role in Irritable Bowel Syndrome: New Therapeutic Strategies. World J Gastroenterol. 2016 Feb 21;22(7):2219-41. PubMed PMID: 26900286.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. AU - Distrutti,Eleonora, AU - Monaldi,Lorenzo, AU - Ricci,Patrizia, AU - Fiorucci,Stefano, PY - 2015/05/28/received PY - 2015/12/05/revised PY - 2015/12/30/accepted PY - 2016/2/23/entrez PY - 2016/2/24/pubmed PY - 2017/1/18/medline KW - Antibiotics KW - Fecal transplantation KW - Gut microbiota KW - Irritable bowel syndrome KW - Prebiotics KW - Probiotics KW - Synbiotics SP - 2219 EP - 41 JF - World journal of gastroenterology JO - World J Gastroenterol VL - 22 IS - 7 N2 - In the last decade the impressive expansion of our knowledge of the vast microbial community that resides in the human intestine, the gut microbiota, has provided support to the concept that a disturbed intestinal ecology might promote development and maintenance of symptoms in irritable bowel syndrome (IBS). As a correlate, manipulation of gut microbiota represents a new strategy for the treatment of this multifactorial disease. A number of attempts have been made to modulate the gut bacterial composition, following the idea that expansion of bacterial species considered as beneficial (Lactobacilli and Bifidobacteria) associated with the reduction of those considered harmful (Clostridium, Escherichia coli, Salmonella, Shigella and Pseudomonas) should attenuate IBS symptoms. In this conceptual framework, probiotics appear an attractive option in terms of both efficacy and safety, while prebiotics, synbiotics and antibiotics still need confirmation. Fecal transplant is an old treatment translated from the cure of intestinal infective pathologies that has recently gained a new life as therapeutic option for those patients with a disturbed gut ecosystem, but data on IBS are scanty and randomized, placebo-controlled studies are required. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/26900286/Gut_microbiota_role_in_irritable_bowel_syndrome:_New_therapeutic_strategies_ L2 - https://www.wjgnet.com/1007-9327/full/v22/i7/2219.htm DB - PRIME DP - Unbound Medicine ER -